related announcements
News
Healthcare
Johnson & Johnson
06/28/2024 | Press release | Distributed by Public on 06/28/2024 09:32
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Sharing and Personal Tools
Please select the service you want to use:
Smartlinks | Johnson & Johnson | News | Health | Science | Research | Company News | Business Announcement | Products and Services | Securities Issuers | Pharmaceutical Companies | London Stock Exchange (LSE) | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Six Swiss Exchange | Sao Paulo Stock Exchange (B3) | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Santiago Stock Exchange | Bolsa Mexicana de Valores (BMV) | Buenos Aires Stock Exchange (BCBA) | Lima Stock Exchange (BVL) | Colombia Securities Exchange | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Bolsa Electrónica de Chile | Cboe BZX Exchange | Cboe BXE Europe | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | Investors Exchange (IEX) | EuroTLX | Bolsa Institucional de Valores (BIVA) | Hannover Stock Exchange | Nasdaq BX | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago | Turquoise
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact